Research programme: cell based therapeutics - Cell Source

Drug Profile

Research programme: cell based therapeutics - Cell Source

Alternative Names: Anti Third Party Veto Cell - Cell Source; Organsource; T-central memory Veto Cell - Cell Source; TCM Veto Cell - Cell Source

Latest Information Update: 09 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Cell Source
  • Class Cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Transplant rejection

Most Recent Events

  • 04 Nov 2015 Cell based therapeutics - Cell Source are available for licensing as of 04 Nov 2015.
  • 04 Nov 2015 Cell Source files for patent protection with the United States Patent Office for Veto Cell technology in USA
  • 23 Oct 2014 Italian Medicine Association approves IND application for megadose drug combination in Transplant rejection (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top